Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Conference Correspondent  - ESMO Highlights

For cancer cells of ovarian tumors that are deficient in homologous recombination, the inhibition of poly (ADP-ribose) polymerase (PARP) enzymes can result in synthetic lethality by terminating an alternative DNA repair pathway. Although PARP inhibitors have been shown to improve patient survival for a variety of cancer types, their associated safety concerns can negatively affect patient quality of life. In this study, Thein and colleagues undertook a systematic review and meta-analysis of randomized controlled trials (RCTs) published before March 2018 to determine the risk for gastrointestinal (GI) and hepatic toxicities.

In the 3 included phase 3 RCTs with mention of GI toxicities and elevation of liver function tests (LFTs), 1401 patients were eligible. The included study arms used the PARP inhibitors―olaparib, niraparib, or rucaparib―and the control arms utilized placebo, and each of the 3 studies used a 2:1 active:control randomization ratio. The meta-analysis showed that PARP inhibitors increased the risk for all grades of GI and hepatic toxicities, with relative risks (RRs) of 1.29 for diarrhea (95% confidence interval [CI], 1.05-1.58; P = .015), 1.73 for dyspepsia (95% CI, 1.20-2.49; P = .003), 2.11 for nausea (95% CI, 1.86-2.40; P <.001), 2.20 for vomiting (95% CI, 1.76-2.75; P <.001), 4.38 for dysgeusia (95% CI, 3.00-6.41; P <.001), and 4.74 for elevated LFT (95% CI, 2.82-7.95; P <.001). High-grade (grades 3 and 4) side effects were also increased, with RRs of 1.225 for diarrhea (95% CI, 0.992-1.512; P = .060), 4.35 for nausea (95% CI, 1.45-13.06; P = .009), 3.39 for vomiting (95% CI, 1.19-9.63; P = .02), and 10.19 for elevated LFT (95% CI, 2.47-42.06; P = .001).

Given the significant impact that these toxicities may have on patients’ quality of life, and that they may negatively affect compliance rates, the authors suggest that timely intervention with proper supportive care should be considered for patients receiving treatment with PARP inhibitors.


Source

Thein KZ, et al. ESMO 2018. Abstract 969P.

Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO Highlights
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Safety and Efficacy of XMT-1536 in Ovarian Cancer: Subgroup Analysis from a Phase 1 Expansion Study
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Atezolizumab in Patients with Newly Diagnosed Stage III or Stage IV Ovarian Cancer
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Individualized Starting Dose of Niraparib to Treat Platinum-Sensitive Recurrent Ovarian Cancer: The NORA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.